Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80

Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib, have been demonstrated to effectively treat the patients of extracranial non-small cell lung cancer (NSCLC). However, these patients often develop brain metastasis (BM) during their disease course. The major...

Full description

Bibliographic Details
Main Authors: Kuan-Hung Lin, Shu-Ting Hong, Hsiang-Tsui Wang, Yu-Li Lo, Anya Maan-Yuh Lin, James Chih-Hsin Yang
Format: Article
Language:English
Published: MDPI AG 2016-11-01
Series:International Journal of Molecular Sciences
Subjects:
gefitinib
blood–brain barrier (BBB)
liposomes
peptides
lung cancer
Online Access:http://www.mdpi.com/1422-0067/17/12/1998

Internet

http://www.mdpi.com/1422-0067/17/12/1998

Similar Items